A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.